Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital

Cargene关闭了由BioTrack Capital牵头的1920万美元的美国Pre-A轮

2021-12-15 16:00:11 BioSpace


Accelerating nucleic acid therapeutics through innovative chemistry and biology to improve lives worldwide Cargene Biopharma Inc. ("Cargene") announced today the close of an over-subscribed US$19.2 million pre-Series A funding round. The financing was led by BioTrack Capital, with participation from Hyfinity Investments, Legendstar Capital and other investors. Cargene is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics for cardiovascular, fibrotic and pulmonary diseases. With operations in Singapore, USA and China, Cargene aims to improve quality of life for millions of patients worldwide through clinically meaningful treatments generated from its proprietary platforms coupled with deep biology and chemistry insights. Cargene's OSCAR™ algorithm and SMoP™ pharmacophore design platforms work seamlessly together to enable rapid innovation of highly potent, specific and stable siRNAs against any target. The first programmes to leverage on this synergic combination are cardiovascular disease and non-alcoholic steatohepatitis (NASH). To tackle the most critical unmet need in NASH, Cargene has exclusively in-licensed regenerative medicine-related technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis in NASH patients. By inhibiting the targets, the technology has demonstrated the enhancement of liver regeneration in both acute and chronic liver disease models as well as human cell line assays. The development of this technology was funded by the EVX-A*STAR PLATINUM Grant. This grant supports the co-creation of new biotech ventures such as Cargene with A*STAR, and facilitates the development of proof-of-concept R&D in therapeutic platform technologies originating from A*STAR. Cargene is also developing technologies for targeted delivery of oligonucleotides to a variety of organs and tissues, and novel nucleosides to boost pharmaceutical efficacy of the siRNAs. The proceeds from this round will be used to advance Cargene's lead asset to investigational new drug (IND) application and accelerate the Company's technology development. Cargene was jointly founded by XQ Lin, Chairman and founder of EVX Ventures, Dr. Yann Chong Tan, a serial biotech entrepreneur who has co-founded a NASDAQ listed biotech company and Dr.Torsten Wuestefeld, principal investigator at A*STAR's Genome Institute of Singapore. Cargene has a scientific board of world-class scientists comprising Professors Harvey Lodish, Roger Foo, Kausik Ray, and Torsten Wuestefeld. "Cargene reflects EVX's philosophy to invest in technologies that redefine the therapeutics of tomorrow. The cross border scientific ecosystems that Cargene is built upon will help fully realize oligonucleotides' therapeutic potential and create long-lasting and meaningful impact for patients worldwide," said XQ Lin, Chairman & Founder of EVX Ventures and Chairman of Cargene. Qinggang Zhuang, Executive Director of BioTrack Capital, said, "Oligonucleotide therapeutics is a focus area for BioTrack Capital. Cargene has a founding team comprising biotech serial entrepreneurs and world-class experts in nucleic acid chemistry. Leveraging the capabilities of Boston, Singapore and Shanghai, Cargene has established innovative platforms and proprietary siRNA delivery systems with exciting preliminary data. "We are very glad to have the opportunity to lead this early fundraising round and look forward to working with the team to build a leading innovative oligonucleotide drug company." About EVX Ventures EVX Ventures is a global venture builder that focuses on building and incubating biotech companies. With a focus on disruptive therapeutics platform technologies and novel therapeutic modalities, they invest in global technologies to redefine the therapeutics of tomorrow. Learn more at About BioTrack Capital Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. We continually seek to discover innovative biotech companies, innovative medtech companies, and innovative business models in healthcare which are led by outstanding entrepreneurs. Learn more at About Hyfinity Investments Hyfinity Investments are led by senior partners from top-tier investment institutions in China, with years of experiences in healthcare investment, local operation, and overseas licensing. Hyfinity Investments is devoted to advancing the global innovations in diseases with high unmet needs, by leveraging the rich clinical resources in China. Their mission is to foster industry leaders through converging resources globally. Learn more at About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit multimedia:
通过创新的化学和生物学加速核酸治疗以改善全世界的生活 Cargene Biopharma Inc.(“Cargene”)今天宣布,超额认购的1920万美元的美国A轮融资结束。融资由BioTrack Capital牵头,Hyfinity Investments、Legendstar Capital和其他投资者参与。 Cargene是一家临床前阶段生物制药公司,开发用于心血管、纤维化和肺部疾病的寡核苷酸疗法。Cargene在新加坡、美国和中国开展业务,旨在通过其专有平台结合深入的生物学和化学见解产生的具有临床意义的治疗,改善全球数百万患者的生活质量。 Cargene的Oscar™算法和SMOP™药效团设计平台无缝合作,使针对任何目标的高效、特异性和稳定的siRNAs快速创新成为可能。利用这种协同组合的第一个方案是心血管疾病和非酒精性脂肪性肝炎(NASH)。为了解决NASH中最关键的未满足的需求,Cargene拥有新加坡科学、技术和研究机构(A*STAR)独家许可的再生医学相关技术,以减少NASH患者的肝纤维化。通过抑制靶点,该技术在急性和慢性肝病模型以及人类细胞系检测中都证明了增强肝再生。 这项技术的开发由EVX-A*STAR白金赠款资助。这笔赠款支持与A*Star共同创建新的生物技术企业,如Cargene,并促进A*Star在治疗平台技术方面的概念验证研发。 Cargene还在开发将寡核苷酸靶向输送到各种器官和组织的技术,以及新的核苷,以提高siRNAs的药效。此轮融资所得将用于推动Cargene的主要资产用于研究性新药(IND)应用,并加速公司的技术开发。 Cargene由EVX Ventures董事长兼创始人XQ Lin、Yann Chong Tan博士和新加坡a*Star基因组研究所首席研究员Torsten Wuestefeld博士共同创立。Cargene有一个由世界级科学家组成的科学委员会,包括哈维·洛迪什教授、罗杰·富教授、考西克·雷教授和托尔斯滕·武斯特菲尔德教授。 EVX Ventures董事长兼创始人、Cargene董事长林志浩表示:“Cargene反映了EVX投资于重新定义未来治疗学的技术的理念。Cargene所建立的跨境科学生态系统将有助于充分实现寡核苷酸的治疗潜力,并为全球患者创造持久和有意义的影响。” BioTrack Capital执行董事庄庆刚表示:“寡核苷酸治疗是BioTrack Capital关注的领域。Cargene拥有一支由生物技术系列企业家和世界级核酸化学专家组成的创始团队。Cargene利用波士顿、新加坡和上海的能力,建立了创新平台和专有的siRNA传递系统,并提供了令人兴奋的初步数据。 “我们很高兴有机会牵头这一轮早期募资,期待与团队携手打造领先的创新型寡核苷酸药企。” 关于EVX Ventures EVX Ventures是一家全球风险投资公司,专注于建立和孵化生物技术公司。他们专注于颠覆性治疗平台技术和新的治疗模式,投资于全球技术,以重新定义未来的治疗学。在www.evx.ventures了解更多信息 关于BioTrack Capital BioTrack Capital成立于2017年,是一家专注于在中国建设和孵化创新生命科学公司的医疗保健风险投资公司。我们不断寻求发现由杰出企业家领导的创新生物技术公司、创新医疗技术公司和创新医疗商业模式。在www.biotrackcapital.com了解更多信息 关于Hyfinity Investments Hyfinity Investments由来自中国顶级投资机构的资深合伙人领导,在医疗保健投资、本土运营和海外许可方面拥有多年经验。Hyfinity Investments致力于通过充分利用中国丰富的临床资源,推进全球未满足需求疾病的创新。他们的使命是通过汇聚全球资源来培育行业领导者。在www.hyfinityfund.com了解更多信息 关于科学、技术和研究机构(A*STAR) 科学、技术和研究机构(A*STAR)是新加坡领先的公共部门研发机构。通过开放创新,我们与公共和私营部门的合作伙伴合作,为经济和社会造福。作为一个科技组织,a*STAR在学术界和工业界之间架起了桥梁。我们的研究为新加坡创造了经济增长和就业机会,并通过改善医疗保健、城市生活和可持续发展方面的社会结果来改善生活。a*STAR在为更广泛的研究社区和行业培养科学人才和领导者方面发挥着关键作用。A*STAR的研发活动涵盖生物医学科学、物理科学和工程,研究实体主要位于Biopolis和Fusionopolis。有关持续新闻,请访问。 多媒体: